Genetron Holdings (Genetron Health; Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. To expand the potential applications of cancer molecular profiling technology, it partners with genomic sequencing technology and instrumentation enterprises, and biopharmaceutical companies to offer customized services and products.